Healthcare IB at Different Bank Types

Introduction

Not all healthcare banking jobs are the same. The bank you join determines the types of deals you work on, the depth of sub-sector exposure you get, and the exit opportunities available to you. A healthcare analyst at Goldman Sachs has a fundamentally different experience than one at Leerink or Piper Sandler, even though both carry the "healthcare IB" title. Understanding these differences matters for targeting your applications, tailoring your networking, and answering the inevitable "why this bank?" question with specificity.

Healthcare banking is well-represented across every bank type, but each offers a distinct value proposition for analysts. The table below summarizes the key differences.

League Tables

Rankings that track advisory deal volume and value by bank over a given period. Healthcare league tables are published by Refinitiv, Bloomberg, and other data providers. Goldman Sachs led healthcare advisory in 2024 with 193 transactions. League table positioning influences client mandates (companies want top-ranked advisors), but the rankings can be misleading because they count all deal involvement equally regardless of the bank's actual role.

Bulge Bracket Healthcare Groups

The major bulge brackets run the largest healthcare deals. Goldman Sachs, J.P. Morgan, and Morgan Stanley consistently rank in the top three for healthcare M&A advisory by deal count and value. Their healthcare groups cover all five sub-sectors and have full product capabilities, meaning they can advise on a $15 billion pharma acquisition, lead a $300 million biotech IPO, and structure a $5 billion leveraged financing for a PE-backed services roll-up, all within the same group.

For analysts, the advantage is breadth of exposure and exit optionality. The brand carries significant weight in buyside recruiting, and the variety of deal types provides a well-rounded skill set. The tradeoff is less direct client exposure (larger teams, more layers of hierarchy) and the chance that you spend significant time on pitchbooks and comps for deals that never materialize.

Elite Boutiques

Centerview Partners has emerged as the top healthcare sell-side advisory firm, consistently advising on the highest-profile transactions. Evercore, PJT Partners, Lazard, and Moelis also have active healthcare practices. These firms are advisory-only (no capital markets), which means every deal is M&A, restructuring, or strategic advisory.

The smaller team sizes mean analysts get pulled into live deals earlier and have more face time with MDs. But healthcare coverage at most elite boutiques skews heavily toward pharma/biotech M&A (where the largest advisory fees are), with less activity in services or medtech.

Healthcare-Specialist Banks

This category is uniquely important in healthcare. Firms like Leerink (now part of TD Cowen), Piper Sandler, and Jefferies have built their reputations on healthcare sector expertise. Jefferies' healthcare group alone has over 250 professionals. Piper Sandler consistently ranks among the most active healthcare M&A advisors by deal count.

Equity Research as a Deal Origination Engine

At healthcare-specialist banks, equity research analysts covering pharma and biotech companies often serve as a client relationship channel alongside investment bankers. A Leerink or Piper Sandler research analyst who has covered a biotech company for years has deep management relationships that can lead to ECM mandates (IPOs, follow-ons) and eventually M&A advisory. This research-to-banking pipeline is a distinctive feature of healthcare-specialist firms.

What makes these firms compelling for candidates is the depth of immersion. An analyst at a healthcare-specialist bank will build more complex healthcare-specific models (rNPV, pipeline SOTP, payer mix sensitivity) and interact with more healthcare management teams than a generalist analyst at a BB who happens to be staffed in healthcare. The tradeoff is narrower brand recognition outside healthcare: your exit opportunities will skew toward healthcare PE, pharma corporate development, and biotech hedge funds rather than generalist buyside roles.

Middle-Market Banks

Baird, Raymond James, Houlihan Lokey, and similar middle-market banks have active healthcare practices that tend to focus on healthcare services M&A and PE-backed transactions. Deal sizes range from $50 million to $2 billion, and the dominant buyer is private equity.

The analyst experience at middle-market healthcare banks involves high deal volume, heavy sponsor interaction, and deep exposure to roll-up economics and operational value creation. Exit opportunities focus on healthcare PE firms and healthcare-focused growth equity, which is a strong outcome for candidates interested in the healthcare services space.

Your choice should align with your sub-sector interest and career goals:

Regardless of bank type, healthcare IB provides strong career optionality. The sector expertise you develop is transferable across every exit path, and the domain knowledge compounds over time in ways that generalist IB experience does not.